Avior Bio Inc.



September 3, 2019
Avior completes formulation screening study of three prototype formulations of AV104 film in beagle dogs. Results show clear superiority in bioavailability as compared to commercially available RLD sold in ex-US markets.  

Aug 28, 2019 
Avior also completes study proof-of-concept with one prototype formulation of AV103 film as a medical countermeasure (MCM) for patients under opioid induced respiratory depression. Results show that the therapeutic plasma concentration can be achieved in 5 minutes to reverse opioid induced respiratory depression.  

July 22, 2019
Avior files PCT Patent Application for its Speedit™ formulation and method of

July 12, 2019
Avior establishes 1year retest date based on accelerated product stability (40C/75%RH), demonstrate robust manufacturing for AV104 formulations, and signs Phase I clinical trial material (CTM) supply agreement with Protoform, Inc.

March 8, 2019
Avior received SBIR grant award from National Institute of Health.  

January 3, 2019
Avior establishes a developmental laboratory at the Biolabs’ Innovation Center in downtown, Durham, NC.  


November 24, 2018
Avior signs a strategy small-business research loan as debt financing from the NC Biotechnology Center.

November 10, 2018
Quality Chemicals Laboratories further invests in Avior as preferred shares.

October 25, 2018
Avior files additional provisional Patent Application – 870/3 PROV titled – Method and Device of Treating Chronic Kidney Disease associated Pruritus.

September 14, 2018
Avior develops its first prototype formulation using Speedit™ transmucosal delivery


July 12, 2018
Avior develops a dose-proportional Substance P based pharmacodynamic (PD) pruritus model with C57BL mice to demonstrates efficacy of AV104.  Results shows a strong dose response with increasing doses of AV104.

April 12, 2018
Quality Chemical Laboratories (QCL) invests $350,000 in Avior as preferred shares.   

Feb 22, 2018
Avior files for NC incorporation and files its first provisional Patent Application – 870/2 PROV titled – Transmucosal Film Composition and Methods of Making and Using the Same.